```
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MHKAGLLGLCARAWNSVRMASSGMTRRDPLANKVALVTASTDGIGFAIARRLAQDGAHVV 60

Qy     61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120

Qy    121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180

Qy    181 PYNVSKTALLGLTKTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 PYNVSKTALLGLTKTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240

Qy    241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278
          ||||||||||||||||||||||||||||||||||||||
Db    241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278
```

RESULT 3
AAB93414
ID AAB93414 standard; Protein; 278 AA.
XX
AC AAB93414;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:12620.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 12620; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 278 AA;

```
  Query Match           99.7%;  Score 1395;  DB 22;  Length 278;
  Best Local Similarity  99.6%;  Pred. No. 2e-131;
  Matches  277;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 MHKAGLLGLCARAWNSVRMASSGMTRRDPLANKVALVTASTDGIGFAIARRLAQDGAHVV 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MHKAGLLGLCARAWNSVRMASSGMTRRDPLANKVALATASTDGIGFAIARRLAQDGAHVV 60

Qy     61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120

Qy    121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180

Qy    181 PYNVSKTALLGLTKTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 PYNVSKTALLGLTKTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240

Qy    241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278
          ||||||||||||||||||||||||||||||||||||||
Db    241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278
```

RESULT 4
AAY68735
ID AAY68735 standard; Protein; 278 AA.
XX
AC AAY68735;
XX
DT 05-MAY-2000 (first entry)
XX
DE Short chain alcohol dehydrogenase-related molecule ScRM-1 protein.
XX
KW Human; short chain alcohol dehydrogenase-related molecule;
KW SCAD-related molecule; ScRM-1; ScRM-2; metabolic regulator;
KW cell proliferation regulator; inflammation regulator;
KW cell proliferative disorder; immune disorder; arteriosclerosis;
KW atherosclerosis; bursitis; cirrhosis; hepatitis; AIDS;
KW Addison's disease; adult respiratory distress syndrome; allergy;
KW ankylosing spondylitis; amyloidosis; cancer.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 16
FT /note= "potential protein kinase C phosphorylation site"
FT Modified-site 21
FT /note= "potential protein kinase C phosphorylation site"
FT Modified-site 25
FT /note= "potential casein kinase II phosphorylation site
FT and potential protein kinase C phosphorylation
FT site"
FT Modified-site 31
FT /note= "potential protein kinase C phosphorylation site"
FT Region 33..45
FT /note= "SCAD motif"
FT Region 34..51
FT /note= "glucose/ribitol dehydrogenase motif"
FT Binding-site 39..46

```
FT                   /note= "AMP-binding domain"
FT   Modified-site   62
FT                   /note= "potential protein kinase C phosphorylation site"
FT   Modified-site   63
FT                   /note= "potential protein kinase C phosphorylation site"
FT   Region          108..119
FT                   /note= "glucose/ribitol dehydrogenase motif"
FT   Region          108..118
FT                   /note= "SCAD motif"
FT   Region          108..119
FT                   /note= "SCAD motif"
FT   Modified-site   125
FT                   /note= "potential casein kinase II phosphorylation site"
FT   Region          156..172
FT                   /note= "glucose/ribitol dehydrogenase motif"
FT   Region          162..199
FT                   /note= "SCAD motif"
FT   Region          162..213
FT                   /note= "SCAD signature sequence"
FT   Region          169..197
FT                   /note= "SCAD family signature sequence"
FT   Region          182..201
FT                   /note= "glucose/ribitol dehydrogenase motif"
FT   Domain          182..186
FT                   /note= "canonical catalytic site of SCADs"
FT   Region          203..220
FT                   /note= "glucose/ribitol dehydrogenase motif"
FT   Region          204..213
FT                   /note= "SCAD motif"
FT   Modified-site   232
FT                   /note= "potential casein kinase II phosphorylation site
FT                          and potential protein kinase C phosphorylation
FT                          site"
FT   Modified-site   236
FT                   /note= "potential protein kinase C phosphorylation site"
FT   Region          238..258
FT                   /note= "glucose/ribitol dehydrogenase motif"
XX
PN   WO200004135-A2.
XX
PD   27-JAN-2000.
XX
PF   16-JUL-1999;   99WO-US16164.
XX
PR   16-JUL-1998;   98US-0116750.
PR   16-JUL-1998;   98US-0160074.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Bandman O,  Tang YT,  Corley NC,  Azimzai Y,  Baughn MR;
XX
DR   WPI; 2000-171266/15.
DR   N-PSDB; AAZ46090.
XX
PT   New short chain alcohol dehydrogenase polypeptides useful for
PT   diagnosis, treatment and prevention of cell proliferative disorders
PT   such as atherosclerosis, cirrhosis and cancers of various tissues -
XX
PS   Claim 1; Fig 1A-D; 78pp; English.
XX
CC   The present sequence represents a human short chain alcohol dehydrogenase
CC   (SCAD)-related molecule designated ScRM-1. The specification also
CC   describes ScRM-2. ScRM proteins are metabolic, cell proliferation and
CC   inflammation regulators. The ScRM polynucleotides and polypeptides are
CC   used for treating or preventing a cell proliferative or immune disorder
CC   in humans. Cell proliferative disorders include arteriosclerosis,
CC   atherosclerosis, bursitis, cirrhosis, and hepatitis. Immune disorders
CC   include AIDS, Addison's disease, adult respiratory distress syndrome,
CC   allergies, ankylosing spondylitis, and amyloidosis. The vectors,
CC   agonists, antagonists, antibodies and complementary sequences are also
CC   used for treating the above conditions. The polynucleotides and
CC   polypeptides are also used for treating cancers of various tissues
CC   such as adrenal gland, bladder, bone, bone marrow, and brain.
XX
SQ   Sequence   278 AA;

  Query Match            94.9%;  Score 1327;  DB 21;  Length 278;
  Best Local Similarity  96.4%;  Pred. No. 1.3e-124;
  Matches  268;  Conservative    0;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1 MHKAGLLGLCARAWNSVRMASSGMTRRDPLANKVALVTASTDGIGFAIARRLAQDGAHVV 60
           || | |||||| |  ||||||| ||||||| |||||||||||||||||||||||||| ||||
Db       1 MHMARLLGLCAWARKSVRMASSRMTRRDPLTNKVALVTASTDGIGFAIARRLAQDRAHVV 60

Qy      61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 VSSRKQQNVDQAVATLQGEGLSVTGTVCHVGKAEDRERLVATAVKLHGGIDILVSNAAVN 120

Qy     121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 PFFGSIMDVTEEVWDKTLDINVKAPALMTKAVVPEMEKRGGGSVVIVSSIAAFSPSPGFS 180

Qy     181 PYNVSKTALLGLTKTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240
           |||||||||||  ||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 PYNVSKTALLGLNNTLAIELAPRNIRVNCLAPGLIKTSFSRMLWMDKEKEESMKETLRIR 240

Qy     241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278
           |||||||||||||||||||||||||||||||||||||||
Db     241 RLGEPEDCAGIVSFLCSEDASYITGETVVVGGGTPSRL 278


RESULT 5
AAU30722
ID   AAU30722 standard; Protein; 477 AA.
XX
AC   AAU30722;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Novel human secreted protein #1213.
XX
KW   Human; vaccination; gene therapy; nutritional supplement;
KW   stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW   immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200179449-A2.
XX
PD   25-OCT-2001.
XX
PF   16-APR-2001; 2001WO-US08656.
XX
PR   18-APR-2000; 2000US-0552929.
PR   26-JAN-2001; 2001US-0770160.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2001-611725/70.
XX
PT   Nucleic acids encoding a range of human polypeptides, useful in genetic
PT   vaccination, testing and therapy -
XX
PS   Claim 20; Page 336; 765pp; English.
XX
CC   The invention relates to novel human secreted polypeptides. The
CC   polypeptides and antibodies to the polypeptides are useful for
CC   determining the presence of or predisposition to a disease associated
CC   with altered levels of polypeptide. The polypeptides are also useful for
CC   identifying agents (agonists and antagonists) that bind to them. Cells
CC   expressing the proteins are useful for identifying a therapeutic agent
CC   for use in treatment of a pathology related to aberrant expression or
CC   physiological interactions of the polypeptide. Vectors comprising
CC   the nucleic acids encoding the polypeptides and cells genetically
```